Oncopharmpod
Zongertinib
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:12:07
- More information
Informações:
Synopsis
A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.
